NCT04261413已完成1 期
A Multicenter, Open Label, Two-step, Phase Ia/Ib Study of Tumor Targeted Prodrug RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.2 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2021年12月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Dose-limiting toxicities (DLTs)
研究概览
简要总结
This study designed as a multicenter, open label, two-step study to determine the optimum dose, pharmacokinetics, and the safety of RS-0139 in patients with a recurrent, locally advanced or metastatic solid tumors. The research is planned as a two-step study (Phase Ia and phase Ib) and accelerated titration design (ATD) is used.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have consented to participation in the trial.
- •Patients of both sexes aged between 18 and 75 years.
- •Patients with relapsed or refractory solid tumors who have failed available standard therapy or are not candidates for standard therapy.
- •Patients who are willing to provide fresh or archival biopsy material before their participation to identify the integrin expression levels (for Phase Ib only).
- •Patients who completed the previous treatments 21 days before the first dose of the study drug.
- •Patients who have at least three months of life expectancy.
- •Patients with ECOG performance score 0 to
- •Patients with adequate organ function defined as:
- •Hemoglobin ≥10 mg/dl
- •Neutrophil ≥1,500/µL
- •Platelet ≥100,000/µL
- •Creatinine ≤1.5xULN or creatinine clearance ≥60mL/sec/1.73m2
- •Total bilirubin ≤ 1.5xULN
- •AST/ALT ≤2.5xULN; for patients who have confirmed liver metastasis: AST/ALT ≤5xULN.
- •Prothrombin time ≤1.5xULN (in case of no anticoagulant treatment).
- •Normal levels of serum magnesium and potassium concentrations
排除标准
- •Patients with active and/or uncontrolled central nervous system (CNS) metastasis.
- •Patients who have interstitial lung disease or interstitial pneumonia.
- •Patients who have serious cardiac dysfunction.
- •Patients who have insufficient target organ function.
- •Patients with positive tests for HAV, HBV, HCV or HIV.
- •Patients who experienced grade 3 or higher toxicity related to the previous docetaxel treatment.
- •Female patients who are pregnant or breastfeeding.
- •Male patients with pregnant female partners.
- •Patients enrolled in another clinical trial at the same time or recently completed an investigational drug study and received the last dose of an investigational drug within 30 days or five half-lives (whichever is longer).
- •Patients who have serious medical conditions such as uncontrolled infection or untreated wounds.
- •Patients who have bone marrow transplantation history.
- •Patients who have hypersensitivity to docetaxel, components of RS-0139 and/or other taxanes.
- •Patients taking inhibitors or inducers of CYP3A4, including grapefruit juice and OTC medications such as St. John's Wort.
- •Patients who, in the judgment of the PI, are likely to be non-compliant or unable to cooperate.
- •Patients who cannot be contacted in case of emergency.
- •Patients who are the PI or sub-investigator, research assistant, pharmacist, study coordinator or other staff directly involved in conducting the study.
研究组 & 干预措施
RS-0139
Experimental
There will be only RS-0139 arm in the study.
干预措施: RS-0139 (Drug)
结局指标
主要结局
Dose-limiting toxicities (DLTs)
时间窗: At the end of each cycle (Each cycle is 21 days)
The incidence of AEs, serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs).
时间窗: At the end of each cycle (Each cycle is 21 days)
次要结局
- Anti-tumor activity measured by tumor shrinkage (based on CT-scan evaluations)(At the end of Phase Ib (assessed up to 1 year))
- Change in CA 125 / CA15-3 / CA 19-9 / CA 72-4 (depends on the tumor type)(At the end of Phase Ib (assessed up to 1 year))
- Change in circulating tumor cells(At the end of Phase Ib (assessed up to 1 year))
- Objective Response Rate (ORR)(At the end of Phase Ib (assessed up to 1 year))
- Progression-Free Survival (PFS)(At the end of Phase Ib (assessed up to 1 year))
- Duration of Response (DoR)(At the end of Phase Ib (assessed up to 1 year))
- Peak plasma concentration (Cmax)(At the end of the Phase Ia and Ib (assessed up to 1 year))
- AUC(o-t)(At the end of the Phase Ia and Ib (assessed up to 1 year))
- AUC(0-∞)(At the end of the Phase Ia and Ib (assessed up to 1 year))
- tmax(At the end of the Phase Ia and Ib (assessed up to 1 year))
- t1/2(At the end of the Phase Ia and Ib (assessed up to 1 year))
- λz(At the end of the Phase Ia and Ib (assessed up to 1 year))
- CL(At the end of the Phase Ia and Ib (assessed up to 1 year))
- Vss(At the end of the Phase Ia and Ib (assessed up to 1 year))
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast CancerNeoplasms, BreastNCT00251433Novartis Pharmaceuticals53
已完成
1 期
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple MyelomaMultiple MyelomaNCT02685826Celgene56
终止
1 期
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer PatientsAdvanced Hepatocellular Carcinoma (HCC)NCT04212221Zai Lab (Shanghai) Co., Ltd.89
终止
1 期
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or LymphomaSolid TumoursNCT00695448GlaxoSmithKline11
招募中
1 期
Polyspecific Antibodies in Lymphoproliferative T-cell DisordersPeripheral T Cells Lymphoma (PTCL)NCT06495723Xenothera SAS54